Volume 3.03 | Jan 27

Prostate Cell News 3.03, January 27, 2012
     In this issue: Publications | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
PTP1B Is an Androgen Receptor-Regulated Phosphatase that Promotes the Progression of Prostate Cancer
In this study, researchers found that the protein tyrosine phosphatase PTP1B, a well-established regulator of metabolic signaling, was induced after androgen stimulation of androgen receptor-expressing prostate cancer cells. [Cancer Res] Abstract

Watch the Video: Optimize Your ALDHbr Cell Detection with Tissue-Specific ALDEFLUOR™ Protocols
PUBLICATIONS (Ranked by Impact Factor of the Journal)


ARN-509: A Novel Anti-Androgen for Prostate Cancer Treatment
In this study, researchers report the discovery and development of ARN-509, a competitive androgen receptor (AR) inhibitor that is fully antagonistic to AR overexpression, a common and important feature of castration-resistant prostate cancer. [Cancer Res] Abstract

AR Intragenic Deletions Linked to Androgen Receptor Splice Variant Expression and Activity in Models of Prostate Cancer Progression
Researchers’ data demonstrate that structural alterations in the androgen receptor (AR) gene are linked to stable gain-of-function splicing alterations in castration-resistant prostate cancer. [Oncogene] Abstract

Androgen-Regulated miR-32 Targets BTG2 and Is Overexpressed in Castration-Resistant Prostate Cancer
Here, researchers identified several androgen-regulated microRNAs (miRNAs) that may contribute to the development of castration-resistant prostate cancer. [Oncogene] Abstract

Human Prostate Cancer in a Clinically Relevant Xenograft Mouse Model: Identification of Beta(1,6)-Branched Oligosaccharides as a Marker of Tumor Progression
The purpose of this study was to establish xenograft mouse models of metastatic and non-metastatic human prostate cancer and to apply these models for the search of aberrant glycosylation patterns associated with tumor progression in vivo and in patients. [Clin Cancer Res] Abstract

Control of Stability of Cyclin D1 by Quinone Reductase 2 in CWR22Rv1 Prostate Cancer Cells
In this study on the mechanism of prostate cancer prevention by resveratrol, focusing on the role of its recently discovered target protein, quinone reductase 2 (NQO2), researchers generated NQO2 knockdown CWR22Rv1 using short hairpin RNA-mediated gene silencing approach. [Carcinogenesis] Abstract

Critical Role of O-GlcNAc Transferase in Prostate Cancer Invasion, Angiogenesis and Metastasis
Here, researchers show O-linked-ß-N-acetylglucosamine (O-GlcNAc) transferase (OGT) is overexpressed in prostate cancer compared to normal prostate epithelium, and OGT protein and O-GlcNAc levels are elevated in prostate carcinoma cell lines. [J Biol Chem] Abstract

Livin Regulates Prostate Cancer Cell Invasion by Impacting the Nuclear Factor-κB Signaling Pathway and the Expression of FN and CXCR4
In this study, researchers found that the expression of Livin was higher in metastatic prostate cancer tissues than in nonmetastatic tissues and that the expression of Livin was downregulated/upregulated by small interfering RNA/vector, which could inhibit/promote PC-3/LNCaP cell invasion. [IUBMB Life] Abstract

PDGF Upregulates Mcl-1 through Activation of ß-Catenin and Hypoxia-Inducible Factor-1α-Dependent Signaling in Human Prostate Cancer Cells
Using experimental models that closely mimic clinical pathophysiology of prostate cancer (PCa) progression, researchers demonstrated that platelet derived growth factor (PDGF) is a survival factor in PCa cells through upregulation of myeloid cell leukemia-1 (Mcl-1). [PLoS One] Abstract

Inhibition of Androgen-Responsive LNCaP Prostate Cancer Cell Tumor Xenograft Growth by Dietary Phenethyl Isothiocyanate Correlates with Decreased Angiogenesis and Inhibition of Cell Attachment
In this tumor cell xenograft model, dietary administration of phenethyl isothiocyanate inhibited androgen-responsive LNCaP human prostate cancer cell tumor growth. [Int J Oncol] Abstract


Dutasteride in Localized Prostate Cancer Management: The REDEEM Randomized, Double-Blind, Placebo-Controlled Trial
Researchers aimed to investigate the safety and efficacy of dutasteride, a 5α-reductase inhibitor, on prostate cancer progression in men with low-risk disease who chose to be followed up with active surveillance. [Lancet] Abstract | Press Release

Seven Years of Experience with High-Intensity Focused Ultrasound for Prostate Cancer: Advantages and Limitations
The aim of this study was to evaluate oncologic outcomes and adverse events for patients with prostate cancer after treatment by high-intensity focused ultrasound. [Prostate] Abstract

Cholesterol and the Risk of Grade-Specific Prostate Cancer Incidence: Evidence from Two Large Prospective Cohort Studies with up to 37 Years’ Follow Up
Researchers suggest that men with higher cholesterol are at greater risk of developing high-grade prostate cancer but not overall risk of prostate cancer. [BMC Cancer] Abstract

Detect 7 times more prostate epithelial progenitors with ProstaCult


Researcher Studies Foods, Dietary Supplements that May Reduce Risk of Prostate Cancer
A Kansas State University professor, Brian Lindshield, is turning to nutrition to tackle prostate cancer. The goal of his research is twofold: He is performing basic studies that examine specific drugs as well as dietary supplements. [Kansas State University] Press Release

Research to Shed Light on Bone Metastasis in Prostate Cancer
A team of Wayne State University School of Medicine researchers recently received $363,660 from the National Cancer Institute of the National Institutes of Health for a project that aims to shed new light on implications for bone metastasis in prostate cancer. [Wayne State University School of Medicine]
Press Release

Anti-Prostate Cancer Agent Orteronel (TAK-700) Enters into Phase III Clinical Trials in Japan
Takeda Pharmaceutical Company Limited and Millennium: The Takeda Oncology Company announced that Takeda Bio Development Center Limited has initiated enrollment of patients in Japan for the two ongoing global Phase III clinical trials for the anti-prostate cancer investigational agent, TAK-700. [Takeda Pharmaceutical Company Limited] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW 17th Annual Scottsdale Prostate Cancer Symposium 2012
March 1-4, 2012
Scottsdale, United States

NEW Global Congress on Prostate Cancer
June 28-30, 2012
Brussels, Belgium

Visit our events page to see a complete list of events in the prostate cell community.


Research and Development Technologist, hPSC Media (STEMCELL Technologies) 

Scientist – Pluripotent Stem Cells (STEMCELL Technologies)

Scientific Marketing Communications Specialist (STEMCELL Technologies Inc.)

Research Technologist, Manufacturing Sciences (STEMCELL Technologies)

Business Analyst – Product Management (STEMSOFT Software)

Research Associate – Development (Precision Therapeutics, Inc.)

Postdoctoral Research Fellow – Epidemiology / Prostate Studies (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellow (Baylor College of Medicine)

Postdoctoral Position – Cancer Research (Weill Cornell Medical College and Cold Spring Harbor Laboratory)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe,
Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!


Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives | Events | Contact Us